Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 27, 2025
Context: This filing reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries.
Key Financial Metrics
Share Repurchase Programme Status:
- Total Programme Cap: Up to DKK 20 billion (12-month period beginning February 6, 2024).
- Current Sub-Programme: Initiated November 11, 2024, with a cap of DKK 3,136,206,122.30 (ending February 3, 2025).
- Accumulated Repurchases (Current Sub-Programme): 4,018,074 B shares for a total value of DKK 2,781,626,352 as of January 24, 2025.
- Accumulated Repurchases (Total Programme since Feb 6, 2024): 24,221,173 B shares for a total value of DKK 19,645,420,230.
- Average Share Price (Total Programme): DKK 811.08 per B share.
Treasury Shares:
- Total Treasury Shares Owned: 25,365,731 B shares.
- Percentage of Share Capital: 0.6%.
- Total Share Capital (A and B shares): 4,465,000,000 shares.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Recent Transactions (January 20–24, 2025):
The company executed five transactions under the current sub-programme, purchasing a total of 529,807 B shares for approximately DKK 309.2 million. Average purchase prices ranged from DKK 568.07 to DKK 619.09.
Programme Progress:
As of January 24, 2025, the company has utilized approximately 98.2% of the total DKK 20 billion authorised for the 12-month period starting February 6, 2024.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the remaining balance of the DKK 20 billion programme during the 12-month period beginning February 6, 2024.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the share repurchase programme under EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining balance of the DKK 20 billion share repurchase programme (approximately DKK 354.6 million remaining as of Jan 24, 2025).
- Confirm the final transaction date for the current sub-programme (February 3, 2025).
- Review the impact of the 0.6% treasury share holding on earnings per share (EPS) calculations.
- Monitor the average purchase price trend, noting recent transactions were executed below the programme-wide average of DKK 811.08.